Spero Therapeutics, Inc. (SPRO) |
|
1.43 0.06 (4.38%)
|
03-24 16:00 |
|
Open: |
1.35 |
Pre. Close: |
1.37 |
|
High:
|
1.4402 |
Low:
|
1.35 |
|
Volume:
|
296,429 |
Market Cap:
|
74(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:30:05 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.86  One year: 2.04 |
| Support: |
Support1: 1.35 Support2: 1.12 |
| Resistance: |
Resistance1: 1.59 Resistance2: 1.75 |
| Pivot: |
1.46 |
| Moving Average: |
MA(5): 1.38 MA(20): 1.47
MA(100): 1.75 MA(250): 1.87 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 9.6 %D(3): 8.1 |
| RSI: |
RSI(14): 41.5 |
| 52-week: |
High: 8.78 Low: 0.68 |
| Average Vol(K): |
3-Month: 444 (K) 10-Days: 527 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SPRO ] has closed above bottom band by 40.5%. Bollinger Bands are 23.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.44 - 1.45 |
1.45 - 1.45 |
|
Low:
|
1.34 - 1.34 |
1.34 - 1.35 |
|
Close:
|
1.42 - 1.43 |
1.43 - 1.44 |
|
Company Description |
|
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Tue, 21 Mar 2023
Should You Accumulate Spero Therapeutics Inc (SPRO) Stock Tuesday Morning? - InvestorsObserver
Mon, 13 Mar 2023
Is Spero Therapeutics Inc (SPRO) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Mon, 06 Mar 2023
Spero Therapeutics to Provide Business Update and Report Fourth ... - GlobeNewswire
Thu, 23 Feb 2023
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround - Yahoo Finance
Sat, 14 Jan 2023
individual investors who own 39% along with institutions invested in Spero Therapeutics, Inc. (NASDAQ:SPRO) saw increase in their holdings value last week - Simply Wall St
Mon, 14 Nov 2022
Glaxosmithkline Ups Stake in Spero Therapeutics Inc (SPRO) - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
52 (M) |
| Shares Float |
37 (M) |
|
% Held by Insiders
|
24.7 (%) |
|
% Held by Institutions
|
38.3 (%) |
|
Shares Short
|
468 (K) |
|
Shares Short P.Month
|
849 (K) |
Stock Financials |
|
EPS
|
-3.53 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.51 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-952.5 |
|
Return on Assets (ttm)
|
-50.2 |
|
Return on Equity (ttm)
|
-141.9 |
|
Qtrly Rev. Growth
|
-34.5 |
|
Gross Profit (p.s.)
|
-0.82 |
|
Sales Per Share
|
0.17 |
|
EBITDA (p.s.)
|
-1.61 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-80 (M) |
|
Levered Free Cash Flow
|
-41 (M) |
Stock Valuations |
|
PE Ratio
|
-0.41 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.31 |
|
Price to Sales
|
8.4 |
|
Price to Cash Flow
|
-0.94 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
